Abstract
MicroRNAs have been predicted to regulate the stability and translation of many target mRNAs that are involved in modulating disease outcome. Thus, valuable strategies to enhance or to diminish the function of microRNAs are needed to manipulate microRNA-mediated target gene expression. Recently, it has become apparent that one class of antisense oligonucleotides, locked nucleic acids, can be used to sequester microRNAs in the liver of a variety of animals including humans, opening the possibility of applying locked nucleic acid-mediated gene therapy. This review summarizes the success of sequestration of liver-specific microRNA miR-122 by antisense locked nucleic acids and their use in combating hepatitis C virus in clinical trials.
Keywords: Clinical trials, gene targeting, hepatitis C virus, locked nucleic acids, microRNA-mRNA interactions, viral gene expression.
Current Gene Therapy
Title:Combating Hepatitis C Virus by Targeting MicroRNA-122 Using Locked Nucleic Acids
Volume: 12 Issue: 4
Author(s): Erica S. Machlin, Peter Sarnow and Selena M. Sagan
Affiliation:
Keywords: Clinical trials, gene targeting, hepatitis C virus, locked nucleic acids, microRNA-mRNA interactions, viral gene expression.
Abstract: MicroRNAs have been predicted to regulate the stability and translation of many target mRNAs that are involved in modulating disease outcome. Thus, valuable strategies to enhance or to diminish the function of microRNAs are needed to manipulate microRNA-mediated target gene expression. Recently, it has become apparent that one class of antisense oligonucleotides, locked nucleic acids, can be used to sequester microRNAs in the liver of a variety of animals including humans, opening the possibility of applying locked nucleic acid-mediated gene therapy. This review summarizes the success of sequestration of liver-specific microRNA miR-122 by antisense locked nucleic acids and their use in combating hepatitis C virus in clinical trials.
Export Options
About this article
Cite this article as:
Machlin S. Erica, Sarnow Peter and Sagan M. Selena, Combating Hepatitis C Virus by Targeting MicroRNA-122 Using Locked Nucleic Acids, Current Gene Therapy 2012; 12 (4) . https://dx.doi.org/10.2174/156652312802083558
DOI https://dx.doi.org/10.2174/156652312802083558 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vasculopathy in Hyperthyroid Rats and Targets for Drug Effects
Vascular Disease Prevention (Discontinued) Usefulness of Home Blood Pressure in the Diagnosis and Control of Hypertension in Primary Care
Current Hypertension Reviews Dipyridamole: A Drug with Unrecognized Antioxidant Activity
Current Topics in Medicinal Chemistry Role of Micronutrients on Subclinical Atherosclerosis Micronutrients in Subclinical Atherosclerosis
Current Pharmaceutical Design Cytomegalovirus Infection in Pediatric Immunocompromised Hosts
Infectious Disorders - Drug Targets Sepsis and Solid Organ Transplantation
Current Drug Targets Pleiotropic Effects of Omega-3 Fatty Acids
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Endoglin-Targeted Cancer Therapy
Current Drug Delivery Metabolic Syndrome and Cognitive Decline
Current Alzheimer Research Recent Patents on Polymeric Scaffolds for Tissue Engineering
Recent Patents on Biomedical Engineering (Discontinued) Therapeutic Strategies in HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP)
Central Nervous System Agents in Medicinal Chemistry Angiotensin (1-7) and other Angiotensin Peptides
Current Pharmaceutical Design Low Activity of Plasminogen Activator: A Common Feature of Non- Iatrogenic Comorbidities of Schizophrenia
CNS & Neurological Disorders - Drug Targets Assessment and Clinical Relevance of Non-Fasting and Postprandial Triglycerides: An Expert Panel Statement
Current Vascular Pharmacology NF-κB as a Therapeutic Target for Transcription Factor Decoy Strategy in Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Nutraceuticals as Lipid-Lowering Treatment in Pregnancy and Their Effects on the Metabolic Syndrome
Current Pharmaceutical Biotechnology Hormone Replacement Therapy and Stroke
Current Vascular Pharmacology The Immunologic Barriers to Replacing Damaged Organs
Current Immunology Reviews (Discontinued) Update in Pharmacological Management of Coronary No-Reflow Phenomenon
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of ECG in the Diagnosis of Left Ventricular Hypertrophy
Current Cardiology Reviews